Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.710
+0.080 (4.91%)
At close: Oct 29, 2024, 4:00 PM
1.700
-0.010 (-0.58%)
After-hours: Oct 29, 2024, 7:56 PM EDT
Akebia Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Net Income | -40.44 | -51.93 | -94.23 | -282.02 | -384.84 | -279.66 | |
| Depreciation & Amortization | 41.82 | 41.85 | 37.7 | 37.97 | 34.69 | 38.65 | |
| Asset Writedown & Restructuring Costs | - | 0.78 | 8.77 | - | 114.43 | 2.05 | |
| Loss (Gain) From Sale of Investments | - | - | - | -0.02 | -0.05 | -0.82 | |
| Stock-Based Compensation | 7.77 | 9.32 | 17.85 | 22.74 | 24.46 | 11.93 | |
| Other Operating Activities | 1.09 | -2.68 | -41.8 | 73.98 | 113.78 | 69.48 | |
| Change in Accounts Receivable | -10.19 | 0.99 | 11.3 | -24.03 | 11.67 | -22.2 | |
| Change in Inventory | -32.73 | -2.54 | 19.09 | -24.95 | 6.16 | -29.14 | |
| Change in Accounts Payable | 6.09 | -5.24 | 1.5 | -11.74 | 3.68 | 1.37 | |
| Change in Unearned Revenue | - | -3.74 | 4.65 | 1.82 | -32.39 | -39.74 | |
| Change in Other Net Operating Assets | -12.37 | -10.2 | -37.98 | -46.72 | -1.97 | -9.36 | |
| Operating Cash Flow | -38.97 | -23.38 | -73.15 | -252.97 | -110.39 | -257.44 | |
| Capital Expenditures | -0.03 | - | -0.11 | -0.06 | -0.32 | -6.66 | |
| Investment in Securities | - | - | - | 40 | -39.69 | 217.83 | |
| Investing Cash Flow | -0.03 | - | -0.11 | 39.94 | -40 | 211.18 | |
| Long-Term Debt Issued | - | - | - | - | 19.98 | 77.67 | |
| Long-Term Debt Repaid | - | -32 | -33 | - | - | -15 | |
| Net Debt Issued (Repaid) | -0.1 | -32 | -33 | - | 19.98 | 62.67 | |
| Issuance of Common Stock | 25.73 | 6.79 | 7.6 | 88.95 | 211.75 | 26.73 | |
| Repurchase of Common Stock | - | - | - | - | - | -0.43 | |
| Other Financing Activities | -0.75 | - | 40 | 44.78 | - | - | |
| Financing Cash Flow | 24.88 | -25.21 | 14.6 | 133.73 | 231.72 | 88.97 | |
| Net Cash Flow | -14.13 | -48.59 | -58.67 | -79.29 | 81.33 | 42.71 | |
| Free Cash Flow | -39 | -23.38 | -73.27 | -253.02 | -110.71 | -264.1 | |
| Free Cash Flow Margin | -22.35% | -12.02% | -25.05% | -119.55% | -37.57% | -78.83% | |
| Free Cash Flow Per Share | -0.20 | -0.12 | -0.40 | -1.52 | -0.80 | -2.23 | |
| Cash Interest Paid | 6.06 | 6.06 | 6.76 | 9.63 | 7.84 | 0.78 | |
| Levered Free Cash Flow | 52.9 | 22.11 | -15.3 | -136.04 | -17.99 | -193.35 | |
| Unlevered Free Cash Flow | 57.57 | 25.88 | -5.5 | -123.53 | -12.42 | -193.34 | |
| Change in Net Working Capital | -28.96 | -2.53 | 39.28 | 41.76 | -37.82 | 62.77 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.